Skip to main content
Sign In

University of Colorado Denver

​​​​​​​​​ ​
 

Philip Reigan, PhD

Assistant Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences


Mailing address:

University of Colorado School of Pharmacy
Mail Stop C238
12850 E. Montview Blvd. V20-2102
Aurora, CO 80045

Office Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2102

Lab Location:

Pharmacy and Pharmaceutical Sciences Building (V20)
Second Floor
Room 2210, 2420E(S)

Contact:

Affiliation:

  • Member - University of Colorado Cancer Center
  • Member - Colorado Clinical and Translational Sciences Institute

Training and Education:

  • BSc, University of Manchester, UK (Chemistry)
  • MSc, University of Manchester, UK (Pharmacology)
  • PhD, University of Manchester, UK (Medicinal Chemistry)
  • Postdoctoral Fellow, University of Colorado
  • MRSC, Member of the Royal Society of Chemistry

Research Interests:

My laboratory studies the design, synthesis and biological evaluation of small-molecule antitumor agents that act on molecular targets associated with the pathology of cancer. Our current research efforts are focused on developing agents for the treatment of brain tumors. The effective treatment of brain tumors presents a number of challenges, the therapeutic agent needs to cross the blood-brain barrier, localize to a specific region of the brain and exhibit tumor selectivity. Our approach involves several strategies which include the development of:

  1. Computational-based molecular modeling for anticancer drug design, understanding the interaction of the drug with the molecular target, and the prediction of ADMET and passive blood-brain partitioning
  2. Novel antiangiogenic agents that target the catalytic activity or protein-protein interactions of proangiogenic proteins
  3. Prodrugs that target specific enzymes and membrane transporters in the blood-brain barrier to enhance brain delivery of anticancer agents
  4. Prodrugs that exploit the catalytic activity of enzymes overexpressed by tumors to selectively generate the active agent(s) at the tumor site
  5. Novel agents that potentiate the antitumor activity of established anticancer therapeutics by targeting mechanisms of tumor resistance.


The response to our antitumor agents and prodrugs will be examined using in vitro and in vivo systems, which we aim to develop and use to improve our knowledge of the basic molecular and cellular biology of brain tumors. This approach could lead to further innovative strategies for drug targeting through the elucidation of tumor resistance mechanisms. In addition, we are also developing neuroprotective agents that selectively protect normal brain tissue from reactive oxygen species generated from exposure to radiotherapy and chemotherapy. These agents act as alternative electron acceptors and may also prevent free radical-mediated tissue damage during ischemia-reperfusion injury and may have application in neurodegenerative and cardiovascular disease.

Publications:

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reigan%20P%22%5BAuthor%5D